Cervical Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

CERCA MCID: CRV035 MIFTS: 73	Cervical Cancer (CERCA) Categories: Cancer diseases, Genetic diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Cervical Cancer

MalaCards integrated aliases for Cervical Cancer:

Name: Cervical Cancer ⁵⁷ ¹¹ ⁷⁵ ⁷³ ⁵³ ⁴¹ ² ¹⁴ ⁶³ ⁷¹

Neoplasm of Uterine Cervix ¹¹ ²⁸ ⁵

Cervical Cancer, Somatic ⁵⁷ ¹² ⁵

Uterine Cervical Neoplasm ¹¹ ⁷¹

Cervix Cancer ¹¹ ⁷³

Uterine Cervical Neoplasms ⁴³

Tumor of the Cervix Uteri ¹¹

Cancer, Cervical, Somatic ³⁸

Malignant Tumor of Cervix ⁷¹

Uterine Cervical Cancer ⁷³

Cervix Uteri Cancer ¹¹

Neoplasms Cervical ⁵³

Cervical Neoplasm ¹¹

Cervix Carcinoma ⁷¹

Cervical Cancers ¹⁴

Cerca ⁷³

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of cervix uteri

External Ids:

Disease Ontology ¹¹ DOID:4362

OMIM® ⁵⁷ 603956

ICD9CM ³⁴ 180

MeSH ⁴³ D002583

NCIt ⁴⁹ C2940 C9311

SNOMED-CT ⁶⁸ 123841004 254885005

ICD10 ³¹ C53

MedGen ⁴⁰ C0302592 C4048328

SNOMED-CT via HPO ⁶⁹ 108369006 363346000

UMLS ⁷¹ C0007847 C0007873 C0302592 more

Sources

Summaries for Cervical Cancer

MedlinePlus: ⁴¹ The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection. Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer. NIH: National Cancer Institute

MalaCards based summary: Cervical Cancer, also known as neoplasm of uterine cervix, is related to cervix carcinoma and human papillomavirus infectious disease, and has symptoms including pelvic pain An important gene associated with Cervical Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Breast cancer pathway and Interleukin-4 and Interleukin-13 signaling. The drugs Nicotine and Meperidine have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and lymph node, and related phenotypes are neoplasm and abnormality of the cervical spine

CDC: ² Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix connects the vagina (birth canal) to the upper part of the uterus. The uterus (or womb) is where a baby grows when a woman is pregnant. All women are at risk for cervical cancer. It occurs most often in women over age 30. Human papillomavirus (HPV) is the main cause of cervical cancer. HPV is a common virus that is passed from one person to another during sex. At least half of sexually active people will have HPV at some point in their lives, but few women will get cervical cancer. Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

PubMed Health : ⁶³ Cervical cancer: Cervical cancer is the term used to describe tumors that can grow at the lower end of the womb. These tumors usually develop from abnormal cell changes at the entrance to the womb from the vagina (the opening of the cervix). Abnormal cell changes can be detected through screening and then removed. A vaccine against viruses that cause cancer (HPV vaccine) can reduce the risk of cervical cancer. The cervix (neck of the womb) is a strong, muscular tube-like structure. The very bottom end of the cervix sticks out into the vagina a little, at the opening of the cervix. The inside of the cervix is lined with a mucous membrane. Glands in the mucous membrane produce a thick liquid (cervical mucus) that acts as a barrier, preventing germs from entering the womb from the vagina.

UniProtKB/Swiss-Prot: ⁷³ A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

Disease Ontology: ¹¹ A female reproductive organ cancer that is located in the cervix.

Wikipedia: ⁷⁵ Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

More information from OMIM: 603956

Sources

Related Diseases for Cervical Cancer

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1064)

#	Related Disease	Score	Top Affiliating Genes
1	cervix carcinoma	32.8	TP53 MIR214 MIR21 FGFR3 CCND1
2	human papillomavirus infectious disease	32.7	TP53 MIR21 CCND1
3	adenocarcinoma	32.4	TP53 STAT3 MALAT1 H19 FGFR3 CCND1
4	squamous cell carcinoma	32.2	UCA1 TUG1 TP53 STAT3 NEAT1 MALAT1
5	endometrial cancer	31.7	UCA1 TUG1 TP53 STAT3 NEAT1 MIR21
6	retinoblastoma	31.6	TP53 MALAT1 HOTAIR CCND1 CCAT1
7	b-cell lymphoma	31.6	TUG1 TP53 STAT3 PVT1 MALAT1 HOTAIR
8	head and neck cancer	31.4	TP53 STAT3 MIR21 GAS5 CCND1
9	esophageal cancer	31.3	UCA1 TP53 STAT3 PVT1 MIR214 MIR21
10	oropharynx cancer	31.3	TP53 MIR21 CCND1
11	colonic benign neoplasm	31.3	TP53 STAT3 MIR21 CCND1
12	lung cancer susceptibility 3	31.3	TUG1 TP53 STAT3 MIR214 MIR21 MALAT1
13	ovarian cancer	31.2	UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
14	melanoma	31.2	UCA1 TP53 STAT3 PVT1 MIR21 MALAT1
15	lip and oral cavity cancer	31.2	TP53 MIR21 CCND1
16	squamous cell carcinoma, head and neck	31.1	TP53 STAT3 MIR214 MIR21 HOTAIR H19
17	leukemia, chronic lymphocytic	31.1	TP53 STAT3 NEAT1 MIR214 MIR21 CCND1
18	lymphoma	31.1	TP53 STAT3 PVT1 GAS5 CCND1
19	breast cancer	31.0	UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
20	esophagus squamous cell carcinoma	31.0	TUG1 SNHG16 PVT1 MALAT1 HOTAIR GAS5
21	leukemia, acute myeloid	31.0	UCA1 TUG1 TP53 STAT3 MIR21 MALAT1
22	leukemia	31.0	TP53 STAT3 NEAT1 HOTAIR GAS5 CDKN2B-AS1
23	bladder cancer	31.0	UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
24	lymphoma, hodgkin, classic	30.9	TP53 STAT3 PVT1 MIR21
25	hepatocellular carcinoma	30.9	UCA1 TUG1 TP53 STAT3 PVT1 NEAT1
26	colorectal cancer	30.9	UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
27	plasmacytoma	30.9	PVT1 GAS5 CCND1
28	connective tissue disease	30.9	TP53 STAT3 MIR214 MIR21 FGFR3 CCND1
29	ovarian epithelial cancer	30.9	MALAT1 HOTAIR H19 CCAT1
30	kidney cancer	30.9	TP53 PVT1 MIR214 MIR21 MALAT1 HOTAIR
31	lung cancer	30.9	UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
32	acute promyelocytic leukemia	30.8	TP53 STAT3 PVT1 NEAT1 CCND1
33	burkitt lymphoma	30.8	TP53 STAT3 PVT1 NEAT1 MIR21
34	skin squamous cell carcinoma	30.8	TP53 MIR21 HOTAIR CCND1
35	colorectal adenoma	30.8	TP53 MIR21 CCND1
36	bone cancer	30.8	TP53 STAT3 MIR214 MIR21 CCND1
37	rhabdomyosarcoma	30.8	TP53 STAT3 H19 FGFR3 CCND1
38	peripheral t-cell lymphoma	30.8	TP53 STAT3 MIR21 FGFR3
39	teratoma	30.8	TP53 STAT3 H19
40	gastric cancer	30.7	UCA1 TUG1 TP53 STAT3 SNHG16 PVT1
41	small cell cancer of the lung	30.7	TUG1 TP53 MIR21 MALAT1 HOTAIR
42	osteogenic sarcoma	30.7	UCA1 TUG1 TP53 PVT1 NEAT1 MALAT1
43	lymphangioma	30.7	TP53 STAT3 CCND1
44	atypical teratoid rhabdoid tumor	30.7	TP53 HOTAIR CCND1
45	thyroid carcinoma	30.7	UCA1 PVT1 NEAT1 MALAT1 HOTAIR H19
46	nasopharyngeal carcinoma	30.7	TP53 STAT3 PVT1 NEAT1 MIR214 MIR21
47	laryngeal squamous cell carcinoma	30.7	TP53 STAT3 NEAT1 MIR21 MALAT1 HOTAIR
48	brain cancer	30.7	TP53 STAT3 MIR214 MIR21
49	diabetes mellitus	30.7	TUG1 TP53 STAT3 PVT1 MIR21 MALAT1
50	type 2 diabetes mellitus	30.7	TP53 STAT3 PVT1 MIR214 MIR21 GAS5

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis	Deficiency Anemia
Hydronephrosis	Intestinal Obstruction
Vaginal Cancer

Graphical network of the top 20 diseases related to Cervical Cancer:

Sources

Symptoms & Phenotypes for Cervical Cancer

Human phenotypes related to Cervical Cancer:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	neoplasm ³⁰			HP:0002664
2	abnormality of the cervical spine ³⁰			HP:0003319

Clinical features from OMIM®:

603956 (Updated 08-Dec-2022)

UMLS symptoms related to Cervical Cancer:

pelvic pain

Sources

Drugs & Therapeutics for Cervical Cancer

PubMed Health treatment related to Cervical Cancer: ⁶³

The most appropriate type of treatment will mainly depend on the size of the tumor and whether the cancer has spread. If the tumor is discovered at a very early stage, a small surgical procedure (conization ) might be enough. If the tumor has already spread to the surrounding tissue , doctors usually recommend having surgery to remove the entire womb (a hysterectomy ). The lymph nodes are removed in a wide area around the womb too. Radiotherapy might also be considered. Radiotherapy is still an option even if the tumor can no longer be removed through surgery. In some patients it can be combined with chemotherapy .

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 380)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Nicotine

Approved

Phase 4

54-11-5

942 89594

Meperidine

Approved

Phase 4

57-42-1

4058

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Diazepam

Approved, Illicit, Investigational, Vet_approved

Phase 4

439-14-5

3016

Aluminum hydroxide

Approved, Investigational

Phase 4

21645-51-2

Bethanechol

Approved

Phase 4

674-38-4

2370

Bupropion

Approved

Phase 4

31677-93-7, 34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Ferrous fumarate

Approved

Phase 4

141-01-5

Iron

Approved

Phase 4

7439-89-6

29936

Ascorbic acid

Approved, Nutraceutical

Phase 4

50-81-7

54676860 54670067 5785

Rivoceranib

Investigational

Phase 4

811803-05-1

11315474

Epoetin Alfa

Phase 4

Psychotropic Drugs

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, General

Phase 4

Analgesics, Opioid

Phase 4

Narcotics

Phase 4

Monophosphoryl lipid A

Phase 4

Central Nervous System Stimulants

Phase 4

Nicotinic Agonists

Phase 4

Cholinergic Agents

Phase 4

Vitamins

Phase 4

Trace Elements

Phase 4

Micronutrients

Phase 4

Muscarinic Agonists

Phase 4

Dopamine Uptake Inhibitors

Phase 4

Dopamine Agents

Phase 4

Antidepressive Agents

Phase 4

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Fluorodeoxyglucose F18

Phase 4

Valproic acid

Approved, Investigational

Phase 3

99-66-1

3121

Hydralazine

Approved

Phase 3

86-54-4

3637

Fluspirilene

Approved, Investigational

Phase 3

1841-19-6

3396

Metronidazole

Approved

Phase 2, Phase 3

443-48-1, 69198-10-3

4173

Cetirizine

Approved

Phase 3

83881-51-0

2678

Famotidine

Approved

Phase 3

76824-35-6

3325 5702160

Histamine

Approved, Investigational

Phase 3

51-45-6

774

Diphenhydramine

Approved, Investigational

Phase 3

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

Phase 3

60-87-7

4927

Aluminum sulfate

Approved

Phase 3

10043-01-3

Octreotide

Approved, Investigational

Phase 3

83150-76-9

383414 6400441

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 3

9005-49-6

22833565 9812414 772

Reviparin

Approved, Investigational

Phase 3

9041-08-1

Vinblastine

Approved

Phase 3

865-21-4

241903 13342

Vindesine

Approved, Investigational

Phase 3

59917-39-4, 53643-48-4

40839

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

4112 126941

Ondansetron

Approved, Withdrawn

Phase 3

99614-02-5

4595

Granisetron

Approved, Investigational

Phase 3

109889-09-0

3510 5284566

Aprepitant

Approved, Investigational

Phase 3

170729-80-3

6918365 135413536

Interventional clinical trials:

(show top 50) (show all 1551)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer	Unknown status	NCT02629510	Phase 4	Tachosil
2	A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer	Unknown status	NCT03206684	Phase 4	PEG-rhG-CSF;rhG-CSF
3	Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study.	Unknown status	NCT03349463	Phase 4	Fluciclovine F18
4	Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China	Unknown status	NCT01021904	Phase 4
5	Comparison of Meperidine and Fentanyl on Pain Scale and Quality of Life in Cervical Cancer Patients Receiving Brachytherapy: A Double-blind, Randomized Controlled Trial	Completed	NCT02684942	Phase 4	Meperidine;Fentanyl
6	HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico	Completed	NCT03105856	Phase 4
7	Effective Surveillance and Impact of HPV Vaccination on Screening for Cervical Cancer in Tuscany	Completed	NCT02296255	Phase 4
8	Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin)	Completed	NCT00046969	Phase 4	cisplatin
9	Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA	Completed	NCT02910596	Phase 4	bethanechol chloride
10	Enhancing Tobacco Use Treatment for African American Light Smokers	Completed	NCT00666978	Phase 4	bupropion hydrochloride
11	Alternate Dosing Schedules Study for HPV Vaccine	Completed	NCT00862810	Phase 4
12	A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates.	Completed	NCT01953107	Phase 4
13	Does Intraoperative Application of TachoSil Reduce the Number of Lymphocele After Pelvic Lymphadenectomy?	Completed	NCT03752606	Phase 4
14	Patient Navigation in the Safety Net:CONNECTeDD	Completed	NCT00613275	Phase 4
15	Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients.	Completed	NCT01101750	Phase 4
16	Comparing the Lozenge to the Patch for Smoking Cessation	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
17	Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies.	Completed	NCT03384511	Phase 4	Apatinib
18	Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls	Completed	NCT01173900	Phase 4
19	A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women	Completed	NCT01544478	Phase 4
20	Work Package 4: HPV Vaccination of Women in Screening Ages	Completed	NCT02837926	Phase 4
21	A Study to Assess the Immunogenicity Consistency of Three Consecutive Batches of Commercial-scale of Recombinant Human Papillomavirus(HPV) Bivalent Vaccine (Escherichia Coli) in Healthy Female Subjects Aged 9-14 Years	Completed	NCT05426148	Phase 4
22	Application of KANG FU PEN (Protective Irrigation Solution Against Rays) in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury：a Multicenter, Prospective, Randomized Trail	Recruiting	NCT04819685	Phase 4	KANG FU PEN
23	Concomitant HPV Vaccination and HPV Screening for Rapid Elimination of HPV Infection and Cervical Cancer in Sweden	Recruiting	NCT04910802	Phase 4
24	Randomized Controlled Trial to Evaluate the Efficacy of Concurrent Liquid-based Cytology ( LBC) and HPV DNA Testing Versus LBC Alone for the Primary Cervical Cancer Screening	Active, not recruiting	NCT01895517	Phase 4
25	Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India	Active, not recruiting	NCT00923702	Phase 4
26	Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities	Terminated	NCT00629993	Phase 4
27	A Post-marketing Surveillance (PMS) Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in 3,000 Healthy Female Filipino Subjects When Administered According to the Prescribing Information From the Age of 10 Years Onwards.	Terminated	NCT00730847	Phase 4
28	Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer Compared With 18F FDG PET	Terminated	NCT03423082	Phase 4	18F fluciclovine
29	Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients, A Multicenter, Prospective and Randomized Controlled Trial	Unknown status	NCT03308591	Phase 3	NACT;Adjuvant chemotherapy
30	Clinical Study on Docetaxel Plus Cisplatin(TP) Regimen Combined With Postoperative Radiotherapy for Stage Ia2- IIb Cervical Cancer	Unknown status	NCT01999933	Phase 2, Phase 3	cisplatin（DDP） weekly;docetaxel plus cisplatin
31	Improvement of Locally Advanced Cervical Cancer Radiotherapy Efficacy by Use of Volumetric Arc Therapy, Individualized Polyradiosensitization and Interstitial Brachytherapy	Unknown status	NCT02957266	Phase 3	Cisplatin;Gemcitabine
32	A Phase III Randomised Trial Investigating the Benefits of the Addition of Modulated Electro-hyperthermia to Chemo-radiation for Cervical Cancer in HIV Positive and Negative Women in South Africa	Unknown status	NCT03332069	Phase 3	Cisplatin
33	A Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer(CSEM005)	Unknown status	NCT02629718	Phase 3	NACT (Paclitaxel + Cisplatin or carboplatin)
34	A Phase III Randomized Trial Between 5 Day 3 Weekly and Weekly Cisplatin Based Chemotherapy for Patients With Locally Advanced Cervical Cancer	Unknown status	NCT00548821	Phase 3	Cisplatin
35	Multicenter Study on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy With Cisplatin and Docetaxel Combined With Radiotherapy for Local Advanced Cervical Cancer	Unknown status	NCT02703961	Phase 3	concurrent chemotherapy with cisplatin;concurrent chemotherapy with docetaxel;adjuvant chemotherapy with cisplatin and docetaxel
36	Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer	Unknown status	NCT02595554	Phase 3	Paclitaxel;Cisplatin
37	Randomized Controlled Trial Comparing Concurrent Chemoradiation Versus Concurrent Chemoradiation Followed by Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients	Unknown status	NCT02036164	Phase 3	Cisplatin;Paclitaxel;Carboplatin
38	a Prospective Random Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer	Unknown status	NCT04138992	Phase 2, Phase 3	bevacizumab;DDP;Docetaxel
39	Phase III Trial for Primary Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in PET/CT Defined Poor-Prognostic Cervical Cancer Patients	Unknown status	NCT00842660	Phase 3	Gemzar (gemcitabine)
40	Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer.	Unknown status	NCT00532818	Phase 3	Hydralazine and magnesium valproate;Placebo
41	Phase III Randomized Trial of Comparing CCRT vs. RT Alone for Cervical Cancer Patients Primarily Treated by Radiotherapy and With Clinically Defined Good-prognosis	Unknown status	NCT00846508	Phase 3	Cisplatin
42	Individualized Precise Radiotherapy With the Guidance of Radiosensitivity: A Study on the Clinical Management Model of Locally Advanced Cervical Cancer	Unknown status	NCT03163979	Phase 2, Phase 3
43	A Study of QL1604 Plus Chemotherapy Versus Chemotherapy Plus Placebo With Stage ⅣB, Recurrent, or Metastatic Cervical Cancer	Unknown status	NCT04864782	Phase 2, Phase 3	QL1604;Paclitaxel injection;Cisplatin/Carboplatin
44	Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer	Unknown status	NCT00039338	Phase 3	cisplatin
45	Phase III Clinical Trial: "Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer	Unknown status	NCT02446652	Phase 3	Hydralazine/Magnesium;Placebo;Carboplatin;Paclitaxel
46	A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image	Unknown status	NCT00146458	Phase 3
47	Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation	Unknown status	NCT01095198	Phase 2, Phase 3
48	Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy	Unknown status	NCT01755845	Phase 3	paclitaxel;cisplatin
49	A Prospective, Randomized Phase III Study to Compare the Effects of Paclitaxel and Topotecan to Those of Cisplatin and Topotecan for Treatment of Patients With Recurrent and Persistent Cervical Cancer	Unknown status	NCT01405235	Phase 3	Paclitaxel;Cisplatin/Paclitaxel
50	Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy	Unknown status	NCT01756170	Phase 3	paclitaxel;cisplatin

Search NIH Clinical Center for Cervical Cancer

Cochrane evidence based reviews: uterine cervical neoplasms

Sources

Genetic Tests for Cervical Cancer

Genetic tests related to Cervical Cancer:

#	Genetic test	Affiliating Genes
1	Neoplasm of Uterine Cervix ²⁸

Sources

Anatomical Context for Cervical Cancer

Organs/tissues related to Cervical Cancer:

FMA: Cervix

MalaCards : Cervix, Uterus, Lymph Node, Breast, T Cells, Colon, Prostate

Sources

Publications for Cervical Cancer

Articles related to Cervical Cancer:

(show top 50) (show all 35506)

#	Title	Authors	PMID	Year
1	Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. ⁵³ ⁶² ⁵⁷ ⁵	Crook T...Vousden KH	1349102	1992
2	Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. ⁵⁷ ⁵	Cappellen D...Radvanyi F	10471491	1999
3	Somatic LKB1 mutations promote cervical cancer progression. ⁵³ ⁶² ⁵⁷	Wingo SN...Castrillon DH	19340305	2009
4	Integrated genomic and molecular characterization of cervical cancer. ⁶² ⁵⁷	Cancer Genome Atlas Research Network...Washington University in St Louis	28112728	2017
5	PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. ⁶² ⁵⁷	McIntyre JB...Doll CM	23266353	2013
6	Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial. ⁶² ⁴¹	Hu Y...Li K	36471257	2022
7	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
8	Landscape of genomic alterations in cervical carcinomas. ⁵⁷	Ojesina AI...Meyerson M	24390348	2014
9	MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. ⁶² ⁴⁶	Yang Z...Tang H	19859982	2009
10	Patterns of known and novel small RNAs in human cervical cancer. ⁶² ⁴⁶	Lui WO...Fire A	17616659	2007
11	Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. ⁵⁷	Kang S...Dong SM	17360030	2007
12	Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. ⁵	Logie A...Radvanyi F	15772091	2005
13	Genetic link to cervical tumours. ⁵⁷	Magnusson PK...Gyllensten UB	10403244	1999
14	Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. ⁵	Tavormina PL...Wasmuth JJ	8589699	1995
15	Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. ⁵⁷	Hampton GM...Bird CC	8041728	1994
16	Mutational hotspot in the p53 gene in human hepatocellular carcinomas. ⁵	Hsu IC...Harris CC	1849234	1991
17	A genetic model for colorectal tumorigenesis. ⁵⁷	Fearon ER...Vogelstein B	2188735	1990
18	Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit: A Secondary Analysis of a Randomized Clinical Trial. ⁴¹	Winer RL...Buist DSM	36449291	2022
19	Impact of HPV vaccination on HPV infection and cervical related disease burden in real-world settings (HPV-RWS): protocol of a prospective cohort. ⁴¹	Liu Z...Zhan S	36401179	2022
20	HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. ⁵³ ⁶²	Liu J...Guo G	20206160	2010
21	Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV). ⁵³ ⁶²	Guimaraes MC...Soares EG	19786613	2010
22	DeltaNp63alpha repression of the Notch1 gene supports the proliferative capacity of normal human keratinocytes and cervical cancer cells. ⁵³ ⁶²	Yugawa T...Kiyono T	20442293	2010
23	ARL6IP1 mediates cisplatin-induced apoptosis in CaSki cervical cancer cells. ⁵³ ⁶²	Guo F...Li G	20372863	2010
24	Analysis of expression and structure of the TSG101 gene in cervical cancer cells. ⁵³ ⁶²	Broniarczyk J...Gozdzicka-Jozefiak A	20372822	2010
25	Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. ⁵³ ⁶²	Wang H...Yan C	20167600	2010
26	Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. ⁵³ ⁶²	He M...Fu X	20429915	2010
27	Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. ⁵³ ⁶²	Guo F...Li G	20213048	2010
28	Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. ⁵³ ⁶²	McCabe MT...Vertino PM	20193846	2010
29	Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. ⁵³ ⁶²	Oh JM...Juhnn YS	20015862	2010
30	TP53, MDM2, NQO1, and susceptibility to cervical cancer. ⁵³ ⁶²	Hu X...Rader JS	20200430	2010
31	Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. ⁵³ ⁶²	Liao SY...Stanbridge EJ	19913895	2010
32	Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa). ⁵³ ⁶²	Maity G...Chatterjee A	19816757	2010
33	Oncosuppressor proteins of fragile sites are reduced in cervical cancer. ⁵³ ⁶²	Giarnieri E...Mancini R	19700237	2010
34	Anti-angiogenesis agents in metastatic or recurrent cervical cancer. ⁵³ ⁶²	Monk BJ...Sumner DA	19861227	2010
35	Novel missense mutation in FHIT gene: interpreting the effect in HPV-mediated cervical cancer in Indian women. ⁵³ ⁶²	Neyaz MK...Bharadwaj M	19730990	2010
36	[Exploring the issue of cervical cancer prevention and control in women living with HIV/AIDS]. ⁵³ ⁶²	Chuang P...Tsai CM	20127625	2010
37	Gene promoter methylation patterns throughout the process of cervical carcinogenesis. ⁵³ ⁶²	Yang N...van der Zee AG	20208141	2010
38	Use of tissue microarray to facilitate oncology research. ⁵³ ⁶²	Gouveris P...Psyrri A	20217582	2010
39	Kinetics of transport and phosphorylation of glucose in cancer cells. ⁵³ ⁶²	Rodriguez-Enriquez S...Moreno-Sanchez R	19681047	2009
40	The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer. ⁵³ ⁶²	Kang MK...Kim BG	19949677	2009
41	[Mechanism of anti-tumor effect of HIF-1alpha silencing on cervical cancer in nude mice]. ⁵³ ⁶²	Jiang JH...Cheng YX	20137345	2009
42	Tristetraprolin: a weapon against HPV-induced cervical cancer? ⁵³ ⁶²	Gallouzi IE...Di Marco S	20157555	2009
43	Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells. ⁵³ ⁶²	Gao LJ...Chen C	19878546	2009
44	Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis. ⁵³ ⁶²	Flatley JE...Powers HJ	19755648	2009
45	MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. ⁴⁶	Yao Q...Qu LH	19682430	2009
46	Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. ⁵³ ⁶²	Byun JY...Lee SJ	19574249	2009
47	The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. ⁵³ ⁶²	Sanduja S...Dixon DA	20157568	2009
48	Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. ⁵³ ⁶²	Beskow C...Viktorsson K	19672258	2009
49	Immunohistochemical expression of ubiquitin and telomerase in cervical cancer. ⁵³ ⁶²	Morelva Tde M...Antonio LB	19680685	2009
50	The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women. ⁵³ ⁶²	Tian Q...Xie X	19820361	2009

Sources

Genes for Cervical Cancer

Genes related to Cervical Cancer (4 elite genes):

(show top 50) (show all 182)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	1224.1	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative variation ⁷³ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	8589699 10471491 15772091 (more) 11114733 18794123 15105428
2	TP53	Tumor Protein P53	Protein Coding	451.6	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1849234 1349102 26619011 (more) 16681751 14756543 10895031 12445252 17375700 11535556 15908516 11836622 16481734 12144822 10794489 14764039 12618167 8674566 20200430 8774641 10754463 8806692 15640620 9742979 19625214 15899386 18313527 16761419 15790450 14529662 12144687 17012841 17178878 10726657 8942499 1322252 11429213 9155557 16488468 17912468 11485021 11174479 7909855 10741285 10775508 10918193 12451999 17192686 17177838 12821336 12713987 16544983 16054204 15994823 14678586 12499281 10023783 8674061 16841142 18599197 11158620 11212257 10618709 9367711 7591279 8172533 20167600 19423538 15581977 15073118 12534455 11996107 10928171 11885807 8546000 7962045 8397367 19012699 16324714 15905603 15797321 15566643 8623835 8388491 16287099 15143339 12406566 10975290 10729761 9704765 9334921 8039779 11072671 10760422 7841033 1933850 17713095 17324262 15047208 14513722 11146234 15863130
3	MIR21	MicroRNA 21	RNA Gene	419.38	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19682430 17616659
4	MIR214	MicroRNA 214	RNA Gene	368.26	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19859982
5	LNMICC	LncRNA Associated With Lymph Node Metastasis In Cervical Cancer	RNA Gene	166.66	Experimental evidence: Regulation ³⁷ GeneCards inferred via : Publications Gene name (show sections)	29229603
6	TMPOP2	Thymopoietin Pseudogene 2	Pseudogene	165.88	Experimental evidence: Regulation ³⁷ GeneCards inferred via : Publications Gene name (show sections)	25007342
7	CCND1	Cyclin D1	Protein Coding	165.49	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	22487937
8	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	165.36	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	29572071
9	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	162.61	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	20213048 21266177 22487937 (more) 22491206 22664915 24757675 24932303 25773124 26242259 26311052 26400521 26798987 26854446 27184657 27658300
10	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	161.84	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8570220 15525575
11	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	157.07	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	22487937 24748337 25366139 (more) 25405331 25547435 26109871 26152361 26523512 27184657 27229487 27323817 27467165 27574106 27683269 27736969 27897239 28600545 28745272 29335299 29336659 29572071
12	PVT1	Pvt1 Oncogene	RNA Gene	156.56	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	27232880 27272214 27775803 (more) 28276314
13	GAS5	Growth Arrest Specific 5	RNA Gene	156.55	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	22487937 25400758 28472815 (more) 28671039
14	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	156.22	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29207151
15	TUG1	Taurine Up-Regulated 1	Protein Coding	156.19	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28088836 29029428
16	UCA1	Urothelial Cancer Associated 1	RNA Gene	156.1	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	16914571 17416635 28414550 (more) 29523226
17	CCEPR	Cervical Carcinoma Expressed PCNA Regulatory LncRNA	RNA Gene	156.09	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	25921283 28239824 29427865
18	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	155.95	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	22487937 26408699 27899255 (more) 28550682
19	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	155.83	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28849215 28978096
20	SNHG16	Small Nucleolar RNA Host Gene 16	RNA Gene	155.76	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	29126969
21	CCAT2	Colon Cancer Associated Transcript 2	RNA Gene	155.72	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26983975
22	CRNDE	Colorectal Neoplasia Differentially Expressed	RNA Gene	155.67	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29194035
23	SNHG12	Small Nucleolar RNA Host Gene 12	RNA Gene	155.58	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	29533945
24	BLACAT1	BLACAT1 Overlapping LEMD1 Locus	Protein Coding	155.5	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29456724
25	NNT-AS1	NNT Antisense RNA 1	RNA Gene	155.49	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	28628975
26	SPRY4-IT1	SPRY4 Intronic Transcript 1	RNA Gene	155.47	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27642559
27	ZNF667-AS1	ZNF667 Antisense RNA 1 (Head To Head)	RNA Gene	155.43	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29243775
28	BCAR4	Breast Cancer Anti-Estrogen Resistance 4	RNA Gene	155.41	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	28112728
29	HOXA11-AS	HOXA11 Antisense RNA	RNA Gene	155.41	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27792998
30	HAGLR	HOXD Antisense Growth-Associated Long Non-Coding RNA	RNA Gene	155.18	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴
31	PCAT1	Prostate Cancer Associated Transcript 1	RNA Gene	155	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	29687842
32	POLR1HASP	POLR1H Antisense, Pseudogene	Pseudogene	154.98	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	26328261
33	TP53COR1	Tumor Protein P53 Pathway Corepressor 1	RNA Gene	154.97	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	22487937
34	PAX8-AS1	PAX8 Antisense RNA 1	RNA Gene	154.92	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	27225188
35	TUSC8	Tumor Suppressor Candidate 8	RNA Gene	154.88	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24667250
36	LINC01101	Long Intergenic Non-Protein Coding RNA 1101	RNA Gene	154.83	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	28767188
37	NPTN-IT1	NPTN Intronic Transcript 1	RNA Gene	154.82	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25755778
38	EWSAT1	Ewing Sarcoma Associated Transcript 1	RNA Gene	154.79	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	28767188
39	BCYRN1	Brain Cytoplasmic RNA 1	RNA Gene	154.7	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	9422992 29552212
40	PANDAR	Promoter Of CDKN1A Antisense DNA Damage Activated RNA	RNA Gene	154.67	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	29131264
41	MIR100HG	Mir-100-Let-7a-2-Mir-125b-1 Cluster Host Gene	RNA Gene	154.53	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	27035672
42	MIR31HG	MIR31 Host Gene	RNA Gene	154.37	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29129878
43	MIR9-3HG	MIR9-3 Host Gene	RNA Gene	154.34	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	29620291
44	SLC16A1-AS1	SLC16A1 Antisense RNA 1	RNA Gene	153.8	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27363024
45	MEG3	Maternally Expressed 3	RNA Gene	153.76	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	14602737 22487937 23790166 (more) 26574780 27184657 28057015 29620291
46	HTATIP2	HIV-1 Tat Interactive Protein 2	Protein Coding	153.69	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27223436
47	RNY1	RNA, Ro60-Associated Y1	RNA Gene	152.81	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	18283318
48	RNY3	RNA, Ro60-Associated Y3	RNA Gene	152.77	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	18283318
49	APBB3	Amyloid Beta Precursor Protein Binding Family B Member 3	Protein Coding	150	Experimental evidence: Regulation ³⁷	29039612
50	CARD8-AS1	CARD8 Antisense RNA 1	RNA Gene	150	Experimental evidence ³⁷	26147888

Sources

Variations for Cervical Cancer

ClinVar genetic disease variations for Cervical Cancer:

⁵ (show top 50) (show all 144)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TP53	NM_000546.6(TP53):c.747G>T (p.Arg249Ser)	SNV	Pathogenic	12352	rs28934571	GRCh37: 17:7577534-7577534 GRCh38: 17:7674216-7674216
2	FGFR3	NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys)	SNV	Pathogenic Pathogenic	16339	rs121913483	GRCh37: 4:1803568-1803568 GRCh38: 4:1801841-1801841
3	FGFR3	NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys)	SNV	Pathogenic Pathogenic	16332	rs121913482	GRCh37: 4:1803564-1803564 GRCh38: 4:1801837-1801837
4	FGFR3	NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg)	SNV	Pathogenic	16340	rs4647924	GRCh37: 4:1803571-1803571 GRCh38: 4:1801844-1801844
5	FGFR3	NM_000142.5(FGFR3):c.1138G>A (p.Gly380Arg)	SNV	Pathogenic	16327	rs28931614	GRCh37: 4:1806119-1806119 GRCh38: 4:1804392-1804392
6	FGFR3	NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys)	SNV	Pathogenic	16338	rs28933068	GRCh37: 4:1807371-1807371 GRCh38: 4:1805644-1805644
7	FGFR3	NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr)	SNV	Pathogenic	65855	rs121913105	GRCh37: 4:1807890-1807890 GRCh38: 4:1806163-1806163
8	PIK3CA	NM_006218.4(PIK3CA):c.1031T>C (p.Val344Ala)	SNV	Likely Pathogenic	376499	rs1057519941	GRCh37: 3:178921549-178921549 GRCh38: 3:179203761-179203761
9	PIK3CA	NM_006218.4(PIK3CA):c.316G>C (p.Gly106Arg)	SNV	Likely Pathogenic	376480	rs1057519931	GRCh37: 3:178916929-178916929 GRCh38: 3:179199141-179199141
10	FBXW7	NM_001349798.2(FBXW7):c.1973G>A (p.Arg658Gln)	SNV	Likely Pathogenic	376427	rs759610249	GRCh37: 4:153244184-153244184 GRCh38: 4:152323032-152323032
11	TP53	NM_000546.6(TP53):c.394A>C (p.Lys132Gln)	SNV	Likely Pathogenic	376628	rs747342068	GRCh37: 17:7578536-7578536 GRCh38: 17:7675218-7675218
12	TP53	NM_000546.6(TP53):c.395A>C (p.Lys132Thr)	SNV	Likely Pathogenic	376627	rs1057519996	GRCh37: 17:7578535-7578535 GRCh38: 17:7675217-7675217
13	SMAD4	NM_005359.6(SMAD4):c.1082G>C (p.Arg361Pro)	SNV	Likely Pathogenic	376541	rs377767347	GRCh37: 18:48591919-48591919 GRCh38: 18:51065549-51065549
14	TP53	NM_000546.6(TP53):c.581T>C (p.Leu194Pro)	SNV	Likely Pathogenic	376635	rs1057519998	GRCh37: 17:7578268-7578268 GRCh38: 17:7674950-7674950
15	TP53	NM_000546.6(TP53):c.839G>T (p.Arg280Ile)	SNV	Likely Pathogenic	161517	rs121912660	GRCh37: 17:7577099-7577099 GRCh38: 17:7673781-7673781
16	TP53	NM_000546.6(TP53):c.395A>T (p.Lys132Met)	SNV	Likely Pathogenic	376629	rs1057519996	GRCh37: 17:7578535-7578535 GRCh38: 17:7675217-7675217
17	PTEN	NM_000314.8(PTEN):c.388C>G (p.Arg130Gly)	SNV	Likely Pathogenic	375958	rs121909224	GRCh37: 10:89692904-89692904 GRCh38: 10:87933147-87933147
18	HRAS, LRRC56	NM_005343.4(HRAS):c.37G>C (p.Gly13Arg)	SNV	Likely Pathogenic	35554	rs104894228	GRCh37: 11:534286-534286 GRCh38: 11:534286-534286
19	TP53	NM_000546.6(TP53):c.396G>C (p.Lys132Asn)	SNV	Likely Pathogenic	376624	rs866775781	GRCh37: 17:7578534-7578534 GRCh38: 17:7675216-7675216
20	CTNNB1	NM_001904.4(CTNNB1):c.94G>C (p.Asp32His)	SNV	Likely Pathogenic	376054	rs28931588	GRCh37: 3:41266097-41266097 GRCh38: 3:41224606-41224606
21	MAPK1	NM_002745.5(MAPK1):c.964G>A (p.Glu322Lys)	SNV	Likely Pathogenic	376450	rs1057519911	GRCh37: 22:22127164-22127164 GRCh38: 22:21772875-21772875
22	CTNNB1	NM_001904.4(CTNNB1):c.110C>T (p.Ser37Phe)	SNV	Likely Pathogenic	17586	rs121913403	GRCh37: 3:41266113-41266113 GRCh38: 3:41224622-41224622
23	CTNNB1	NM_001904.4(CTNNB1):c.110C>A (p.Ser37Tyr)	SNV	Likely Pathogenic	375894	rs121913403	GRCh37: 3:41266113-41266113 GRCh38: 3:41224622-41224622
24	CTNNB1	NM_001904.4(CTNNB1):c.110C>G (p.Ser37Cys)	SNV	Likely Pathogenic	17579	rs121913403	GRCh37: 3:41266113-41266113 GRCh38: 3:41224622-41224622
25	CTNNB1	NM_001904.4(CTNNB1):c.94G>A (p.Asp32Asn)	SNV	Likely Pathogenic	376228	rs28931588	GRCh37: 3:41266097-41266097 GRCh38: 3:41224606-41224606
26	PIK3CA	NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys)	SNV	Likely Pathogenic	376478	rs1057519929	GRCh37: 3:178916854-178916854 GRCh38: 3:179199066-179199066
27	HRAS, LRRC56	NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)	SNV	Likely Pathogenic	12613	rs104894229	GRCh37: 11:534289-534289 GRCh38: 11:534289-534289
28	HRAS, LRRC56	NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)	SNV	Likely Pathogenic	12603	rs104894230	GRCh37: 11:534288-534288 GRCh38: 11:534288-534288
29	HRAS, LRRC56	NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)	SNV	Likely Pathogenic	12606	rs104894228	GRCh37: 11:534286-534286 GRCh38: 11:534286-534286
30	TP53	NM_000546.6(TP53):c.581T>G (p.Leu194Arg)	SNV	Likely Pathogenic	376633	rs1057519998	GRCh37: 17:7578268-7578268 GRCh38: 17:7674950-7674950
31	SMAD4	NM_005359.6(SMAD4):c.1082G>A (p.Arg361His)	SNV	Likely Pathogenic	24832	rs377767347	GRCh37: 18:48591919-48591919 GRCh38: 18:51065549-51065549
32	PIK3CA	NM_006218.4(PIK3CA):c.112C>T (p.Arg38Cys)	SNV	Likely Pathogenic	376493	rs749415085	GRCh37: 3:178916725-178916725 GRCh38: 3:179198937-179198937
33	TP53	NM_000546.6(TP53):c.712T>C (p.Cys238Arg)	SNV	Likely Pathogenic	376576	rs1057519981	GRCh37: 17:7577569-7577569 GRCh38: 17:7674251-7674251
34	TP53	NM_000546.6(TP53):c.580C>T (p.Leu194Phe)	SNV	Likely Pathogenic	127817	rs587780071	GRCh37: 17:7578269-7578269 GRCh38: 17:7674951-7674951
35	TP53	NM_000546.6(TP53):c.712T>G (p.Cys238Gly)	SNV	Likely Pathogenic	376577	rs1057519981	GRCh37: 17:7577569-7577569 GRCh38: 17:7674251-7674251
36	TP53	NM_000546.6(TP53):c.839G>C (p.Arg280Thr)	SNV	Likely Pathogenic	12368	rs121912660	GRCh37: 17:7577099-7577099 GRCh38: 17:7673781-7673781
37	CREBBP	NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys)	SNV	Likely Pathogenic	95047	rs398124146	GRCh37: 16:3788618-3788618 GRCh38: 16:3738617-3738617
38	SMAD4	NM_005359.6(SMAD4):c.1081C>G (p.Arg361Gly)	SNV	Likely Pathogenic	24830	rs80338963	GRCh37: 18:48591918-48591918 GRCh38: 18:51065548-51065548
39	TP53	NM_000546.6(TP53):c.839G>A (p.Arg280Lys)	SNV	Likely Pathogenic	376657	rs121912660	GRCh37: 17:7577099-7577099 GRCh38: 17:7673781-7673781
40	PTEN	NM_000314.8(PTEN):c.389G>C (p.Arg130Pro)	SNV	Likely Pathogenic	142018	rs121909229	GRCh37: 10:89692905-89692905 GRCh38: 10:87933148-87933148
41	TP53	NM_000546.6(TP53):c.395A>G (p.Lys132Arg)	SNV	Likely Pathogenic	376625	rs1057519996	GRCh37: 17:7578535-7578535 GRCh38: 17:7675217-7675217
42	PTEN	NM_000314.8(PTEN):c.389G>A (p.Arg130Gln)	SNV	Likely Pathogenic	7829	rs121909229	GRCh37: 10:89692905-89692905 GRCh38: 10:87933148-87933148
43	PIK3CA	NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys)	SNV	Likely Pathogenic	31944	rs121913273	GRCh37: 3:178936082-178936082 GRCh38: 3:179218294-179218294
44	TP53	NM_000546.6(TP53):c.581T>A (p.Leu194His)	SNV	Likely Pathogenic	376634	rs1057519998	GRCh37: 17:7578268-7578268 GRCh38: 17:7674950-7674950
45	PTEN	NM_000314.8(PTEN):c.389G>T (p.Arg130Leu)	SNV	Likely Pathogenic	376509	rs121909229	GRCh37: 10:89692905-89692905 GRCh38: 10:87933148-87933148
46	GNAS	NM_000516.7(GNAS):c.601C>T (p.Arg201Cys)	SNV	Likely Pathogenic	15933	rs11554273	GRCh37: 20:57484420-57484420 GRCh38: 20:58909365-58909365
47	PTEN	NM_000314.8(PTEN):c.698G>A (p.Arg233Gln)	SNV	Likely Pathogenic	376510	rs770025422	GRCh37: 10:89717673-89717673 GRCh38: 10:87957916-87957916
48	TP53	NM_000546.6(TP53):c.394A>G (p.Lys132Glu)	SNV	Likely Pathogenic	376626	rs747342068	GRCh37: 17:7578536-7578536 GRCh38: 17:7675218-7675218
49	TP53	NM_000546.6(TP53):c.713G>T (p.Cys238Phe)	SNV	Likely Pathogenic	376574	rs730882005	GRCh37: 17:7577568-7577568 GRCh38: 17:7674250-7674250
50	GNAS	NM_000516.7(GNAS):c.602G>A (p.Arg201His)	SNV	Likely Pathogenic	15934	rs121913495	GRCh37: 20:57484421-57484421 GRCh38: 20:58909366-58909366

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

⁷³

#	Symbol	AA change	Variation ID	SNP ID
1	FGFR3	p.Ser249Cys	VAR_004149	rs121913483

Copy number variations for Cervical Cancer from CNVD:

⁶ (show top 50) (show all 142)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13747	1	1	27800000	Gain	EPHB2	Cervical cancer
2	16425	1	124300000	247249719	Arm		Cervical cancer
3	30310	1	241700000	247249719	Gain		Cervical cancer
4	31746	1	30500000	163800000	Gain	AIM2	Cervical cancer
5	32175	1	34400000	39600000	Gain	CDCA8	Cervical cancer
6	47124	10	89600000	98000000	Loss	PTEN	Cervical cancer
7	48645	11	101600000	102400000	Amplification	MMP1	Cervical cancer
8	48646	11	101600000	102400000	Amplification	MMP13	Cervical cancer
9	51761	11	130300000	134452384	Loss		Cervical cancer
10	51791	11	130800000	135006516	Loss	NTM	Cervical cancer
11	51792	11	130800000	135006516	Loss	OPCML	Cervical cancer
12	55435	11	52900000	134452384	Loss		Cervical cancer
13	57095	11	63100000	130300000	Loss	FGF3	Cervical cancer
14	57096	11	63100000	130300000	Loss	MEN1	Cervical cancer
15	57097	6	99389300	99393387	Loss	POU3F2	Cervical cancer
16	57098	11	63100000	130300000	Loss	TRIM29	Cervical cancer
17	59362	11	74700000	85300000	Gain		Cervical cancer
18	77051	13	39500000	52200000	Loss	RB1	Cervical cancer
19	81044	14	100400000	106368585	Gain	AKT1	Cervical cancer
20	97280	16	1	40700000	Loss		Cervical cancer
21	106741	17	1	11200000	Loss	TP53	Cervical cancer
22	108734	17	22200000	28800000	Loss	CCL2	Cervical cancer
23	109725	17	28500000	29700000	Amplification		Cervical cancer
24	109738	17	28800000	35400000	Amplification	ERBB2	Cervical cancer
25	111034	17	34900000	35300000	Amplification		Cervical cancer
26	111283	17	35400000	54900000	Amplification	ABCC3	Cervical cancer
27	112092	17	37856253	37884915	Amplification	ERBB2	Cervical cancer
28	112304	17	38544772	38574202	Amplification	TOP2A	Cervical cancer
29	117589	17	72900000	78774742	Gain		Cervical cancer
30	124103	19	1	30200000	Gain		Cervical cancer
31	124104	19	1	30200000	Loss		Cervical cancer
32	124177	19	1	6900000	Gain	SMARCA4	Cervical cancer
33	124219	19	1	6900000	Gain		Cervical cancer
34	124597	19	1156797	1179434	Deletion	STK11	Cervical Cancer
35	124598	19	1156797	1179434	Deletion	STK11	Cervical cancer
36	130163	19	47800000	57600000	Gain	LIG1	Cervical cancer
37	134165	19	9500000	14500000	Gain		Cervical cancer
38	140388	2	197100000	242951149	Loss	CASP10	Cervical cancer
39	140389	2	197100000	242951149	Loss	CFLAR	Cervical cancer
40	140390	2	197100000	242951149	Loss	PPP1R7	Cervical cancer
41	151917	20	27100000	28400000	Amplification	AHCY	Cervical cancer
42	151918	20	27100000	28400000	Amplification	ASXL1	Cervical cancer
43	151919	20	27100000	28400000	Amplification	MRGBP	Cervical cancer
44	151920	20	27100000	28400000	Amplification	E2F1	Cervical cancer
45	151921	20	27100000	28400000	Amplification	GSS	Cervical cancer
46	151922	20	27100000	28400000	Amplification	KIF3B	Cervical cancer
47	151923	20	27100000	28400000	Amplification	POFUT1	Cervical cancer
48	151924	20	27100000	28400000	Amplification	TPX2	Cervical cancer
49	153446	20	37100000	41100000	Gain	ANIB1	Cervical cancer
50	153736	20	41100000	49200000	Amplification	ADNP	Cervical cancer

Sources

Expression for Cervical Cancer

Genes differentially expressed in tissues of Cervical Cancer patients vs. healthy controls: ³⁵ (show top 50) (show all 70)

#	Gene	Description	Tissue	Up/Dn	Fold Change (log2)	P value
1	KRT1	keratin 1	Uterus	-	5.47	0.000
2	KRTDAP	keratinocyte differentiation associated protein	Uterus	-	4.96	0.000
3	CTHRC1	collagen triple helix repeat containing 1	Uterus	+	4.65	0.000
4	TMPRSS11B	transmembrane serine protease 11B	Uterus	-	4.58	0.000
5	CDKN2A	cyclin dependent kinase inhibitor 2A	Uterus	+	4.45	0.000
6	CMPK2	cytidine/uridine monophosphate kinase 2	Uterus	+	4.32	0.000
7	CRNN	cornulin	Uterus	-	4.25	0.000
8	MAL	mal, T cell differentiation protein	Uterus	-	4.21	0.000
9	DSG1	desmoglein 1	Uterus	-	4.17	0.000
10	ECT2	epithelial cell transforming 2	Uterus	+	4.10	0.000
11	SYCP2	synaptonemal complex protein 2	Uterus	+	3.95	0.000
12	HS6ST2	heparan sulfate 6-O-sulfotransferase 2	Uterus	+	3.94	0.000
13	KIF14	kinesin family member 14	Uterus	+	3.88	0.000
14	IFI44	interferon induced protein 44	Uterus	+	3.88	0.000
15	MMP1	matrix metallopeptidase 1	Uterus	+	3.83	0.001
16	GREB1	growth regulating estrogen receptor binding 1	Uterus	-	3.78	0.000
17	KRT17	keratin 17	Uterus	+	3.71	0.000
18	SPINK7	serine peptidase inhibitor Kazal type 7	Uterus	-	3.70	0.000
19	NUF2	NUF2 component of NDC80 kinetochore complex	Uterus	+	3.70	0.000
20	NCEH1	neutral cholesterol ester hydrolase 1	Uterus	+	3.64	0.000
21	PLSCR1	phospholipid scramblase 1	Uterus	+	3.63	0.000
22	E2F7	E2F transcription factor 7	Uterus	+	3.62	0.000
23	SLF1	SMC5-SMC6 complex localization factor 1	Uterus	+	3.61	0.000
24	INHBA	inhibin subunit beta A	Uterus	+	3.59	0.001
25	DAPL1	death associated protein like 1	Uterus	-	3.57	0.000
26	KRT4	keratin 4	Uterus	-	3.53	0.000
27	SMC4	structural maintenance of chromosomes 4	Uterus	+	3.50	0.000
28	CEP55	centrosomal protein 55	Uterus	+	3.49	0.000
29	LOX	lysyl oxidase	Uterus	+	3.48	0.000
30	ANLN	anillin, actin binding protein	Uterus	+	3.48	0.000
31	ITGB1	integrin subunit beta 1	Uterus	+	3.46	0.000
32	CRISP3	cysteine rich secretory protein 3	Uterus	-	3.46	0.001
33	HELLS	helicase, lymphoid specific	Uterus	+	3.44	0.000
34	KRT19	keratin 19	Uterus	+	3.44	0.002
35	SPP1	secreted phosphoprotein 1	Uterus	+	3.43	0.000
36	CNFN	cornifelin	Uterus	-	3.42	0.000
37	EPCAM	epithelial cell adhesion molecule	Uterus	+	3.39	0.000
38	NDC80	NDC80 kinetochore complex component	Uterus	+	3.35	0.000
39	SCD	stearoyl-CoA desaturase	Uterus	+	3.31	0.000
40	CRCT1	cysteine rich C-terminal 1	Uterus	-	3.31	0.002
41	KRT13	keratin 13	Uterus	-	3.30	0.010
42	CDK1	cyclin dependent kinase 1	Uterus	+	3.30	0.000
43	DDIT4	DNA damage inducible transcript 4	Uterus	+	3.29	0.000
44	ARMT1	acidic residue methyltransferase 1	Uterus	+	3.29	0.000
45	ALOX12	arachidonate 12-lipoxygenase, 12S type	Uterus	-	3.28	0.000
46	ATAD2	ATPase family AAA domain containing 2	Uterus	+	3.27	0.000
47	ZIC2	Zic family member 2	Uterus	+	3.26	0.000
48	ARHGAP21	Rho GTPase activating protein 21	Uterus	+	3.24	0.000
49	LYN	LYN proto-oncogene, Src family tyrosine kinase	Uterus	+	3.24	0.000
50	PPIB	peptidylprolyl isomerase B	Uterus	+	3.23	0.000

Search GEO for disease gene expression data for Cervical Cancer.

Sources

Pathways for Cervical Cancer

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.17	TP53 STAT3 FGFR3 CCND1
2	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.67	TP53 STAT3 CCND1
3	Head and neck squamous cell carcinoma ⁷⁴	11.41	TP53 FGFR3 CCND1
4	miRNAs involved in DNA damage response ⁷⁴	11.32	TP53 MIR21 CCND1
5	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.17	TP53 STAT3 CCND1
6	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	11.01	STAT3 MIR214 MIR21
7	Bladder cancer ⁷⁴	10.73	TP53 FGFR3 CCND1
8	Mammary gland development pathway - Involution (Stage 4 of 4) ⁷⁴	10.4	TP53 STAT3
9	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma ⁷⁴	10.05	UCA1 STAT3 MIR21

Sources

GO Terms for Cervical Cancer

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.73	TP53 STAT3 MIR214 MIR21 CDKN2B-AS1
2	response to leptin	GO:0044321	9.67	STAT3 CCND1
3	negative regulation of miRNA-mediated gene silencing	GO:0060965	9.5	PVT1 NEAT1
4	positive regulation of metalloendopeptidase activity	GO:1904685	9.33	STAT3 MIR21
5	positive regulation of cytokine production involved in inflammatory response	GO:1900017	9.26	STAT3 MIR21 H19
6	negative regulation of superoxide dismutase activity	GO:1901670	8.62	MIR21 H19